Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.

التفاصيل البيبلوغرافية
العنوان:	Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.
المؤلفون:	Guy, Holly¹ holly.guy@fiecon.com, Walder, Lydia¹, Fisher, Mark¹
المصدر:	PharmacoEconomics. Jul2019, Vol. 37 Issue 7, p965-967. 3p.
مصطلحات موضوعية:	COST effectiveness, RESEARCH, OVARIAN cancer treatment, OVARIAN cancer patients, ADP-ribosyltransferases, ONCOLOGY, COMPARATIVE studies, HETEROCYCLIC compounds, RESEARCH methodology, MEDICAL cooperation, OVARIAN tumors, PIPERIDINE, EVALUATION research, INDOLE compounds
مصطلحات جغرافية:	UNITED States
قاعدة البيانات:	Business Source Index

الوصف
تدمد:	11707690
DOI:	10.1007/s40273-019-00803-7